Faeth Therapeutics
FTH
10 hedge funds and large institutions have $515K invested in Faeth Therapeutics in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
10% more capital invested
Capital invested by funds: $466K → $515K (+$48.6K)
0.09% less ownership
Funds ownership: 3.91% → 3.83% (-0.09%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$10.6K |
| 2 |
Citigroup
New York
|
+$2.84K |
| 3 |
BP
BNP Paribas
Paris,
France
|
+$68 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$11.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.25K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.14K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$1.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
1
Ikarian Capital
Dallas,
Texas
| $228K | -$11.1K | -1,146 | -5% |
|
|
CCM
2
Catalio Capital Management
New York
| $157K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $123K | +$10.6K | +1,100 | +11% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $3.27K | -$3.14K | -325 | -52% |
|
|
5
Citigroup
New York
| $3.14K | +$2.84K | +294 | New |
|
6
JP Morgan Chase
New York
| $341 | – | – | – |
|
7
Morgan Stanley
New York
| $107 | – | – | – |
|
8
BNP Paribas Financial Markets
Paris,
France
| $96 | – | – | – |
|
|
BP
9
BNP Paribas
Paris,
France
| $59 | +$68 | +7 | New |
|
|
SS
10
SBI Securities
Tokyo,
Japan
| $43 | -$1.4K | -145 | -97% |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$8.25K | -873 | Closed |
|
FTH Hedge Fund Activity: Q4 2025 in Review
10 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q4 2025, worth a combined $515K — up 10% from $466K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new FTH positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $10.6K. The largest seller was Ikarian Capital, cutting an estimated $11.1K.
- 10 institutional investors held Faeth Therapeutics (FTH) as of Q4 2025, up from 9 in Q3 2025.
- Funds reported $515K of Faeth Therapeutics stock for Q4 2025, up 10% quarter-over-quarter.
- 2 funds opened new Faeth Therapeutics positions in Q4 2025 and 1 closed out, a net change of +1 holder.
- The largest Faeth Therapeutics buyer in Q4 2025 was Renaissance Technologies, an estimated $10.6K added.
- The largest Faeth Therapeutics seller in Q4 2025 was Ikarian Capital, an estimated $11.1K sold.
Based on aggregated 13F filings for Q4 2025.